RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 TURANDOT
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 14
SP 10
OP 11
DO 10.1177/1559897715593916
UL http://mdc.sagepub.com/content/15/14/10.abstract
AB A monoclonal antibody that blocks white blood cell adhesion to gut mucosal cells reduced the symptoms of moderate to severe ulcerative colitis in patients treated for 12 weeks in the randomized double-blind placebo-controlled TURANDOT trial. The antibody dose of 22.5 mg was most effective. No safety issues were evident.